LY6G6D and cancer: Our observations reveal that MMR proficient cancers characterized by less CD8+ T lymphocytes and low expression of PD-1/PD-L1 exhibit enhanced LY6G6D expression and STAT5 activation, implicating Ly6 genes as novel candidates for the development of new targeted therapies [17, 18] (Fig. 5d).